Literature DB >> 31763577

Entrectinib in Two Pediatric Patients With Inflammatory Myofibroblastic Tumors Harboring ROS1 or ALK Gene Fusions.

Srikanth R Ambati1, Emily K Slotkin1, Edna Chow-Maneval2, Ellen M Basu1.   

Abstract

Entities:  

Keywords:  ALK; ROS1; entrectinib; gene fusion; gene rearrangement; inflammatory myofibroblastic tumor

Year:  2018        PMID： 31763577      PMCID： PMC7594679     

Source DB:  PubMed          Journal:  JCO Precis Oncol        ISSN： 2473-4284


× No keyword cloud information.
  24 in total

1.  Crizotinib in ALK-rearranged inflammatory myofibroblastic tumor.

Authors:  James E Butrynski; David R D'Adamo; Jason L Hornick; Paola Dal Cin; Cristina R Antonescu; Suresh C Jhanwar; Marc Ladanyi; Marzia Capelletti; Scott J Rodig; Nikhil Ramaiya; Eunice L Kwak; Jeffrey W Clark; Keith D Wilner; James G Christensen; Pasi A Jänne; Robert G Maki; George D Demetri; Geoffrey I Shapiro
Journal:  N Engl J Med       Date:  2010-10-28       Impact factor: 91.245

2.  Safety and Antitumor Activity of the Multitargeted Pan-TRK, ROS1, and ALK Inhibitor Entrectinib: Combined Results from Two Phase I Trials (ALKA-372-001 and STARTRK-1).

Authors:  Alexander Drilon; Salvatore Siena; Sai-Hong Ignatius Ou; Manish Patel; Myung Ju Ahn; Jeeyun Lee; Todd M Bauer; Anna F Farago; Jennifer J Wheler; Stephen V Liu; Robert Doebele; Laura Giannetta; Giulio Cerea; Giovanna Marrapese; Michele Schirru; Alessio Amatu; Katia Bencardino; Laura Palmeri; Andrea Sartore-Bianchi; Angelo Vanzulli; Sara Cresta; Silvia Damian; Matteo Duca; Elena Ardini; Gang Li; Jason Christiansen; Karey Kowalski; Ann D Johnson; Rupal Patel; David Luo; Edna Chow-Maneval; Zachary Hornby; Pratik S Multani; Alice T Shaw; Filippo G De Braud
Journal:  Cancer Discov       Date:  2017-02-09       Impact factor: 39.397

Review 3.  Recent Advances in Targeting ROS1 in Lung Cancer.

Authors:  Jessica J Lin; Alice T Shaw
Journal:  J Thorac Oncol       Date:  2017-08-14       Impact factor: 15.609

Review 4.  Inflammatory Myofibroblastic Tumors: Current Update.

Authors:  Venkateswar R Surabhi; Steven Chua; Rajan P Patel; Naoki Takahashi; Neeraj Lalwani; Srinivasa R Prasad
Journal:  Radiol Clin North Am       Date:  2016-03-12       Impact factor: 2.303

Review 5.  Shedding light on inflammatory pseudotumor in children: spotlight on inflammatory myofibroblastic tumor.

Authors:  Lillian M Lai; M Beth McCarville; Patricia Kirby; Simon C S Kao; Toshio Moritani; Eve Clark; Kousei Ishigami; Armita Bahrami; Yutaka Sato
Journal:  Pediatr Radiol       Date:  2015-05-12

6.  Inflammatory myofibroblastic tumors harbor multiple potentially actionable kinase fusions.

Authors:  Christine M Lovly; Abha Gupta; Doron Lipson; Geoff Otto; Tina Brennan; Catherine T Chung; Scott C Borinstein; Jeffrey S Ross; Philip J Stephens; Vincent A Miller; Cheryl M Coffin
Journal:  Cancer Discov       Date:  2014-05-29       Impact factor: 39.397

7.  ALK, ROS1 and NTRK3 gene rearrangements in inflammatory myofibroblastic tumours.

Authors:  Hidetaka Yamamoto; Akihiko Yoshida; Kenichi Taguchi; Kenichi Kohashi; Yui Hatanaka; Atsushi Yamashita; Daisuke Mori; Yoshinao Oda
Journal:  Histopathology       Date:  2016-01-19       Impact factor: 5.087

8.  Chromoplectic TPM3-ALK rearrangement in a patient with inflammatory myofibroblastic tumor who responded to ceritinib after progression on crizotinib.

Authors:  A S Mansfield; S J Murphy; F R Harris; S I Robinson; R S Marks; S H Johnson; J B Smadbeck; G C Halling; E S Yi; D Wigle; G Vasmatzis; J Jen
Journal:  Ann Oncol       Date:  2016-10-14       Impact factor: 32.976

9.  Clinical and radiographic response following targeting of BCAN-NTRK1 fusion in glioneuronal tumor.

Authors:  Christopher Alvarez-Breckenridge; Julie J Miller; Tracy T Batchelor; A John Iafrate; Priscilla K Brastianos; Naema Nayyar; Corey M Gill; Andrew Kaneb; Megan D'Andrea; Long P Le; Jesse Lee; Ju Cheng; Zongli Zheng; William E Butler; Pratik Multani; Edna Chow Maneval; Sun Ha Paek; Brian D Toyota; Dora Dias-Santagata; Sandro Santagata; Javier Romero; Alice T Shaw; Anna F Farago; Stephen Yip; Daniel P Cahill
Journal:  NPJ Precis Oncol       Date:  2017-03-20

10.  Detection of known and novel ALK fusion transcripts in lung cancer patients using next-generation sequencing approaches.

Authors:  Julie A Vendrell; Sylvie Taviaux; Benoît Béganton; Sylvain Godreuil; Patricia Audran; David Grand; Estelle Clermont; Isabelle Serre; Vanessa Szablewski; Peter Coopman; Julien Mazières; Valérie Costes; Jean-Louis Pujol; Pierre Brousset; Isabelle Rouquette; Jérôme Solassol
Journal:  Sci Rep       Date:  2017-10-02       Impact factor: 4.379
View more
  4 in total

1.  Case Report: Circulating Tumor Cells as a Response Biomarker in ALK-Positive Metastatic Inflammatory Myofibroblastic Tumor.

Authors:  Paolo Bonvini; Elisabetta Rossi; Angelica Zin; Mariangela Manicone; Riccardo Vidotto; Antonella Facchinetti; Lucia Tombolan; Maria Carmen Affinita; Luisa Santoro; Rita Zamarchi; Gianni Bisogno
Journal:  Front Pediatr       Date:  2021-04-29       Impact factor: 3.418

Review 2.  Molecular Targets for Novel Therapeutics in Pediatric Fusion-Positive Non-CNS Solid Tumors.

Authors:  Wen-I Chang; Claire Lin; Nicholas Liguori; Joshua N Honeyman; Bradley DeNardo; Wafik El-Deiry
Journal:  Front Pharmacol       Date:  2022-01-20       Impact factor: 5.810

Review 3.  ROS1-dependent cancers - biology, diagnostics and therapeutics.

Authors:  Alexander Drilon; Chelsea Jenkins; Sudarshan Iyer; Adam Schoenfeld; Clare Keddy; Monika A Davare
Journal:  Nat Rev Clin Oncol       Date:  2020-08-05       Impact factor: 66.675

4.  Outstanding Response in a Patient With ROS1-Rearranged Inflammatory Myofibroblastic Tumor of Soft Tissues Treated With Crizotinib: Case Report.

Authors:  Danila Comandini; Fabio Catalano; Massimiliano Grassi; Guido Pesola; Rossella Bertulli; Antonio Guadagno; Bruno Spina; Matteo Mascherini; Franco De Cian; Federico Pistoia; Sara Elena Rebuzzi
Journal:  Front Oncol       Date:  2021-06-15       Impact factor: 6.244
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.